A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

This publication has 10 references indexed in Scilit:

• Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
  Neurology, 1997
• Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations
  Neurology, 1997
• Minor Effect of Tolcapone, a Catechol‐ O‐Methyltransferase Inhibitor, on Extracellular Dopamine Levels Modified by Amphetamine or Pargyline: A Microdialysis Study in Anaesthetized Rats
  Basic & Clinical Pharmacology & Toxicology, 1996
• Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
  Journal of Neurology, Neurosurgery & Psychiatry, 1996
• Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.
  British Journal of Clinical Pharmacology, 1995
• Acute Effects of COMT Inhibition on L-DOPA Pharmacokinetics in Patients Treated with Carbidopa and Selegiline
  Clinical Neuropharmacology, 1995
• Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement
  Neuroscience Letters, 1995
• Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats
  European Journal of Pharmacology, 1995
• General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase
  General Pharmacology: The Vascular System, 1994
• Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study
  Brain Research, 1992